Biohaven Pharmaceutical Holding Company Ltd. (BHVN) financial statements (2020 and earlier)
Company profile
| Business Address |
215 CHURCH STREET NEW HAVEN, CT 06510 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 417 | 264 | 131 | ||
| Cash and cash equivalents | 417 | 264 | 131 | ||
| Prepaid expense | 6 | 7 | 5 | ||
| Other current assets | 1 | 0 | 0 | ||
| Other undisclosed current assets | 0 | 0 | |||
| Total current assets: | 423 | 272 | 137 | ||
| Noncurrent Assets | |||||
| Property, plant and equipment | 7 | 6 | 2 | ||
| Long-term investments and receivables | 7 | 11 | 8 | ||
| Long-term investments | 7 | 11 | 8 | ||
| Other undisclosed noncurrent assets | 1 | 0 | 0 | ||
| Total noncurrent assets: | 16 | 18 | 10 | ||
| TOTAL ASSETS: | 439 | 290 | 147 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 47 | 20 | 9 | ||
| Accounts payable | 12 | 11 | 5 | ||
| Accrued liabilities | 36 | 9 | 5 | ||
| Total current liabilities: | 47 | 20 | 9 | ||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 136 | 2 | 1 | ||
| Financial instruments subject to mandatory redemption, settlement terms, share value, amount | 99 | ||||
| Other liabilities | 0 | 2 | 1 | ||
| Derivative instruments and hedges, liabilities | 37 | ||||
| Other undisclosed noncurrent liabilities | 137 | 118 | 4 | ||
| Total noncurrent liabilities: | 273 | 120 | 5 | ||
| Total liabilities: | 320 | 139 | 15 | ||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent | 119 | 151 | 132 | ||
| Common stock | 875 | 554 | 311 | ||
| Additional paid in capital | 67 | 40 | 24 | ||
| Accumulated deficit | (823) | (444) | (203) | ||
| Total stockholders' equity: | 119 | 151 | 132 | ||
| TOTAL LIABILITIES AND EQUITY: | 439 | 290 | 147 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|
| Operating expenses | (392) | (225) | (108) | |
| Operating loss: | (392) | (225) | (108) | |
| Nonoperating expense | (41) | (16) | (19) | |
| Other nonoperating expense | (0) | (0) | (19) | |
| Interest and debt expense | (8) | (0) | (1) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 8 | 0 | 1 | |
| Loss from continuing operations before income taxes: | (434) | (240) | (126) | |
| Income tax expense | (1) | (0) | (1) | |
| Net loss attributable to parent: | (434) | (241) | (127) | |
| Other undisclosed net loss available to common stockholders, basic | (12) | |||
| Net loss available to common stockholders, diluted: | (434) | (241) | (139) | |
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|
| Net loss: | (434) | (241) | (127) | |
| Comprehensive loss, net of tax, attributable to parent: | (434) | (241) | (127) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.